| Schedule of Financial Information Including Significant Segment Expenses by Program |
The following table presents selected financial information with respect to the Company's single operating segment, including significant segment expenses by program, for the years ended March 31, 2026 and 2025: | | | | | | | | | | | | | Year Ended March 31, | | 2026 | | 2025 | | Operating expenses: | (Amounts in thousands) | | Direct research and development expenses by program: | | | | RP1 program costs by study: | | | | | IGNYTE | 9,541 | | | 14,620 | | | ARTACUS | 5,884 | | | 6,934 | | | CERPASS | 4,559 | | | 7,276 | | | IGNYTE-3 | 21,264 | | | 7,183 | | | Other RP1 study costs | 18,523 | | | 10,863 | | | RP2 | 25,953 | | | 12,043 | | | RP3 | 2,674 | | | 4,948 | | Unallocated research and development expenses1: | 132,786 | | | 125,580 | | | Selling, general and administrative | 98,735 | | | 72,180 | | | Total operating expenses | 319,919 | | | 261,627 | | | Loss from operations | (319,919) | | | (261,627) | | | Other income (expense), net | 5,428 | | | $ | 14,798 | | | Loss before income taxes | $ | (314,491) | | | $ | (246,829) | | | Income tax provision | (551) | | | 468 | | | Net loss | (313,940) | | | (247,297) | |
1 Includes personnel-related costs and other costs |